Report Overview

The EU CAR-T Cell Therapy market size is estimated to be at USD 172 million in 2019 and expected to reach USD XX million by 2028 growing at a CAGR of XX%

The backbone of CAR T-cell therapy is T-cell, which are often called the workhorses of the immune system because of their critical role in orchestrating the immune response and killing cells infected by pathogens. The therapy requires drawing blood from patients and separating out the T cells. Next, using a disarmed virus, the T cells are genetically engineered to produce receptors on their surface called chimeric antigen receptors, or CARs. CAR T-cell therapies represent a game-changing weapon in the oncologists arsenal, offering hope to patients who may have exhausted previous treatment options. Ideal hospitals must be able to perform intensive treatment and serve the optimal patient population. The CAR T-cell therapy market will gain prominence due to its curative potential, as well as commercial potential, for life sciences companies



Market Growth Drivers

Factors that drive the EU CAR-T cell therapy market are increasing the number of cancer cases and rising occurrence of hematological cancer. Due to continuous R&D happening in the EU region, also backed by ongoing regulatory approvals of the new therapies. The companies are also focusing on establishing centers for cancer awareness and how this novel therapy would help in cancer treatment, which would further fuel the market. The European Medicine Agencies (EMA) have approved Kymriah and Yescarta which is expected to push the market for further growth during the forecast period